Regulatory Updates (16 Nov 2026)
16 November 2026
Audiences
Industry member
As part of HSA’s ongoing efforts to enhance regulatory clarity and improve regulatory processes, the Medicinal Products Cluster is pleased to share the following updates with industry stakeholders:
1. Industry Consultation on the Revised Minor Variation (MIV) Checklists for Therapeutic Products
HSA invites industry stakeholders to provide feedback on the proposed revised Minor Variation (MIV) checklists for chemical and biological therapeutic products.
The proposed revisions aim to provide greater clarity on the requirements for post-approval changes to registered therapeutic products, thereby facilitating the preparation and submission of MIV applications.
The consultation period is from 16 November to 31 December 2026.
Consultation documents
Please refer to the following consultation documents:
Proposed revised MIV Checklist for Biological Therapeutic Products [PDF, 1.32 MB] (opens in new tab)
Submission of feedback
Industry stakeholders are invited to review the proposed revised checklists and provide feedback using the Consultation Feedback Excel file [XLSX, 23.12 KB] (opens in new tab). Feedback may include comments and suggestions on specific MIV categories, conditions, supporting data requirements or other aspects of the proposed revisions.
Please submit the completed template through the Consultation Form (opens in new tab) by 31 December 2026.
HSA welcomes industry feedback to help ensure that the revised checklists are clear and practical for implementation.
2. Industry Survey on Electronic Product Information (ePI) in Fast Healthcare Interoperability Resources (FHIR) Format
HSA invites industry stakeholders to participate in a short survey on ePI in FHIR format.
The survey seeks to understand industry’s readiness for ePI in FHIR format, anticipated implementation challenges and views on the potential benefits for healthcare professionals and patients.
Please complete the survey (opens in new tab) by 31 December 2026.
